The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Open accessPublished version of a preprint
Abstract
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 therapies is unclear. We created a novel genetically engineered mouse model of HCC that enables interrogation of how different genetic alterations affect immune surveillance and response to immunotherapies. Expression of exogenous antigens in MYC;Trp53−/− HCCs led to T cell–mediated immune surveillance, which was accompanied by decreased tumor formation and increased survival. Some antigen-expressing MYC;Trp53−/− HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway. Accordingly, expression of exogenous antigens in MYC;CTNNB1 HCCs had no effect, demonstrating that β-catenin promoted immune escape, which involved defective recruitment of dendritic cells and consequently impaired T-cell activity. Expression of chemokine CCL5 in antigen-expressing MYC;CTNNB1 HCCs restored immune surveillance. Finally, β-catenin–driven tumors were resistant to anti–PD-1. In summary, β-catenin activation promotes immune escape and resistance to anti–PD-1 and could represent a novel biomarker for HCC patient exclusion. Significance: Determinants of response to anti–PD-1 immunotherapies in HCC are poorly understood. Using a novel mouse model of HCC, we show that β-catenin activation promotes immune evasion and resistance to anti–PD-1 therapy and could potentially represent a novel biomarker for HCC patient exclusion. See related commentary by Berraondo et al., p. 1003. This article is highlighted in the In This Issue feature, p. 983
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a mouse model of HCC, activation of WNT–β-catenin signalling promotes immune escape by impairing recruitment of dendritic cells and interfering with recognition by natural killer cells73.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cited by
Sorted by citations
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationImmunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Self-citationAntigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,570
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies
Zhou, Q., Meng, Y., Li, D., Yao, L., Le, J., Liu, Y., Sun, Y., Zeng, F., Chen, X., & Deng, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01769-5 · Cited by 1,056
Liu, Y., Xun, Z., Ma, K., Liang, S., Li, X., Zhou, S., Sun, L., Liu, Y., Du, Y., Guo, X., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.011 · Cited by 772
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 747
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811
Zhu, A. X., Abbas, A. R., de Galarreta, M. R., Guan, Y., Lu, S., Koeppen, H., Zhang, W., Hsu, C.-H., He, A. R., Ryoo, B.-Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01868-2 · Cited by 652
Self-citationThe liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donné, R., & Lujambio, A. (2022) · Hepatology · doi:10.1002/hep.32740 · Cited by 659
Self-citationAdvances in molecular classification and precision oncology in hepatocellular carcinoma
Rebouissou, S., & Nault, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.017 · Cited by 603
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
Lee, T. K., Guan, X., & Ma, S. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00508-3 · Cited by 463
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C. G., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 466
Magen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02345-0 · Cited by 429
Self-citationTrial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Self-citationThe CCL5/CCR5 Axis in Cancer Progression
Aldinucci, D., Borghese, C., & Casagrande, N. (2020) · Cancers · doi:10.3390/cancers12071765 · Cited by 422
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras‐Murillo, I., Adán‐Barrientos, I., Galán, M. Á., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 418
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citationMechanisms of drug resistance in HCC
Ladd, A. D., Duarte, S. M., Şahin, İ., & Zarrinpar, A. (2023) · Hepatology · doi:10.1097/hep.0000000000000237 · Cited by 379
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 421
Self-citationThe Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
Pinter, M., Jain, R. K., & Duda, D. G. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 352
Zhu, G., Tang, Z., Huang, R., Qu, W., Fang, Y., Yang, R., Tao, C., Gao, J., Wu, X., Sun, H., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00529-z · Cited by 352
Molecular therapies for HCC: Looking outside the box
Faivre, S. J., Rimassa, L., & Finn, R. S. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.010 · Cited by 332
Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression
Huang, D., Wang, Y., Thompson, J. W., Yin, T., Alexander, P. B., Qin, D., Mudgal, P., Wu, H., Liang, Y., Tan, L., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00820-9 · Cited by 323
β-Catenin signaling in hepatocellular carcinoma
Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154515 · Cited by 325
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 336
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 316
The role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 314
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment
Li, X., Xiang, Y., Li, F., Yin, C., Li, B., & Ke, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02293 · Cited by 291
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 313
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Martín‐Orozco, E., Sanchez-Fernandez, A., Ortiz-Parra, I., & Nicolás, M. A.-S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02854 · Cited by 306
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 288
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 297
WNT as a Driver and Dependency in Cancer
Parsons, M. J., Tammela, T., & Dow, L. E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0190 · Cited by 257
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325918 · Cited by 253
Self-citationEmerging immunotherapy for HCC: A guide for hepatologists
Foerster, F., Gairing, S. J., Ilyas, S. I., & Galle, P. R. (2022) · Hepatology · doi:10.1002/hep.32447 · Cited by 245
Wnt signaling pathway in cancer immunotherapy
Zhou, Y., Jiang, X., Luo, H., Meng, X., Chen, M., & Zhu, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.034 · Cited by 241
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
Pinter, M., Scheiner, B., & Peck‐Radosavljevic, M. (2020) · Gut · doi:10.1136/gutjnl-2020-321702 · Cited by 238
De novo and salvage purine synthesis pathways across tissues and tumors
Tran, D. H., Kim, D., Kesavan, R., Brown, H., Dey, T., Soflaee, M. H., Vu, H. S., Tasdogan, A., Guo, J., Bezwada, D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.011 · Cited by 213
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
Self-citationHepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
Giraud, J., Chalopin, D., Blanc, J., & Saleh, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655697 · Cited by 226
Hou, J., Zhang, H., Sun, B., & Karin, M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.014 · Cited by 198
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Liu, Z., Zhou, Z., Dang, Q., Xu, H. M., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 200
Immune checkpoint inhibitor resistance in hepatocellular carcinoma
Wang, Z., Wang, Y., Gao, P., & Ding, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216038 · Cited by 190
WNT signaling and cancer stemness
Katoh, M., & Katoh, M. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220016 · Cited by 188
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
Müller, M., Bird, T. G., & Nault, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.019 · Cited by 182
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
Westcott, P. M. K., Sacks, N. J., Schenkel, J. M., Ely, Z. A., Smith, O. C. G., Hauck, H., Jaeger, A. M., Zhang, D., Backlund, C. M., Beytagh, M. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00247-z · Cited by 187
Biomarkers for Hepatobiliary Cancers
Nault, J., & Villanueva, A. (2020) · Hepatology · doi:10.1002/hep.31175 · Cited by 181
Self-citationYang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6804 · Cited by 172
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer
Shen, H., Liu, B., Xu, J., Zhang, B., Wang, Y., Shi, L., & Cai, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01145-8 · Cited by 172
Li, D., Li, N., Zhang, Y., Fu, H., Feng, M., Schneider, D., Su, L., Wu, X., Zhou, J., Mackay, S., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.011 · Cited by 160
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154
Friend or foe? The elusive role of hepatic stellate cells in liver cancer
Cogliati, B., Yashaswini, C. N., Wang, S., Sia, D., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00821-z · Cited by 159
Self-citationMolecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Haber, P. K., Castet, F., Torres-Martin, M., Andreu-Oller, C., Puigvehí, M., Miho, M., Radu, P., Dufour, J.-F., Verslype, C., Zimpel, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.09.005 · Cited by 145
Self-citationHou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W.-L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 148
Direct targeting of β ‐catenin in the Wnt signaling pathway: Current progress and perspectives
Wang, Z., Li, Z., & Ji, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21787 · Cited by 145
Tumor Plasticity and Resistance to Immunotherapy
Horn, L. A., Fousek, K., & Palena, C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.001 · Cited by 148
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
Kole, C., Charalampakis, N., Tsakatikas, S. A., Vailas, M. G., Moris, D., Gkotsis, E., Kykalos, S., Karamouzis, M. V., & Schizas, D. (2020) · Cancers · doi:10.3390/cancers12102859 · Cited by 144
Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
Shen, J., Shen, H., Ke, L., Chen, J., Dang, X., Liu, B., & Hua, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.815575 · Cited by 138
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Garris, C., & Luke, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1321 · Cited by 146
von Felden, J., Craig, A. J., García‐Lezana, T., Labgaa, I., Haber, P. K., D’Avola, D., Asgharpour, A., Dieterich, D. T., Bonaccorso, A., Torres‐Martín, M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01519-1 · Cited by 139
Self-citationCellular heterogeneity and plasticity in liver cancer
Chan, L., Tsui, Y., Ho, D. W., & Ng, I. O. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.015 · Cited by 145
Hong, J. Y., Cho, H. J., Sa, J. K., Liu, X., Ha, S. Y., Lee, T., Kim, H., Kang, W., Sinn, D. H., Gwak, G., et al. (2022) · Genome Medicine · doi:10.1186/s13073-021-00995-8 · Cited by 136
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 141
Paskeh, M. D. A., Mirzaei, S., Ashrafizadeh, M., Zarrabi, A., & Sethi, G. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s336858 · Cited by 140
Cross-priming in cancer immunology and immunotherapy
Luri‐Rey, C., Teijeira, Á., Wculek, S. K., de Andrea, C. E., Herrero, C., López‐Janeiro, Á., Rodriguez-Ruiz, M. E., Heras‐Murillo, I., Aggelakopoulou, M., Berraondo, P., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00785-5 · Cited by 150
Role of Wnt/β‐Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer
Yuan, S., Tao, F., Zhang, X., Zhang, Y., Sun, X., & Wu, D. (2020) · BioMed Research International · doi:10.1155/2020/9390878 · Cited by 131
Sun, Y., Wu, P., Zhang, Z., Wang, Z., Zhou, K., Song, M., Ji, Y., Zang, F., Lou, L., Rao, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.010 · Cited by 133
Mechanisms of resistance to immune checkpoint inhibitors
Nagasaki, J., Ishino, T., & Togashi, Y. (2022) · Cancer Science · doi:10.1111/cas.15497 · Cited by 130
Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers
Lei, M. M. L., & Lee, T. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.692940 · Cited by 123
Wu, X., Que, H., Li, Q., & Wei, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02363-1 · Cited by 155
Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma
Lehrich, B. M., Zhang, J., Monga, S. P., & Dhanasekaran, R. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.030 · Cited by 126
Self-citationImmune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 138
Molina-Sánchez, P., Ruiz de Galarreta, M., Yao, M. A., Lindblad, K. E., Bresnahan, E., Bitterman, E., Martin, T. C., Rubenstein, T., Nie, K., Golas, J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.08.015 · Cited by 117
Self-citationPu, J., Xu, Z., Nian, J., Fang, Q., Yang, M., Huang, Y., Li, W., Ge, B., Wang, J., & Wei, H. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00556-3 · Cited by 114
Montasser, A., Bèaufrere, A., Cauchy, F., Bouattour, M., Soubrane, O., Albuquerque, M., & Paradis, V. (2020) · Histopathology · doi:10.1111/his.14317 · Cited by 113
Spatiotemporal Metabolic Liver Zonation and Consequences on Pathophysiology
Martini, T., Naef, F., & Tchorz, J. S. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-024831 · Cited by 113
Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis
Zhu, C., Tabas, I., Schwabe, R. F., & Pajvani, U. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00365-6 · Cited by 112
Yang, X., Deng, B., Zhao, W., Guo, Y., Wan, Y., Wu, Z., Su, S., Gu, J., Hu, X., Feng, W., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.029 · Cited by 111
Li, B., Li, Y., Zhou, H., Xu, Y., Cao, Y., Cheng, C., Peng, J., Li, H., Zhang, L., Su, K., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000553 · Cited by 110
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 116
Rizzo, A., Ricci, A. D., Federico, A. D., Frega, G., Palloni, A., Tavolari, S., & Brandi, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.803133 · Cited by 106
Zheng, X., Jin, W., Wang, S., & Ding, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.729705 · Cited by 104
Self-citationMeng, J., Yang, X. F., Huang, J., Tuo, Z., Hu, Y., Liao, Z., Tian, Y., Deng, S., Deng, Y., Zhou, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202300517 · Cited by 106
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Pinter, M., Pinato, D. J., Ramadori, P., & Heikenwalder, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1258 · Cited by 103
Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives
Ronot, M., Chernyak, V., Burgoyne, A. M., Chang, J., Jiang, H., Bashir, M. R., & Fowler, K. J. (2023) · Radiology · doi:10.1148/radiol.221429 · Cited by 103
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Mediratta, K., El‐Sahli, S., D’Costa, V. M., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12123529 · Cited by 102
Trépo, E., Caruso, S., Yang, J., Imbeaud, S., Couchy, G., Bayard, Q., Letouzé, É., Ganne‐Carrié, N., Moreno, C., Oussalah, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00603-3 · Cited by 104
Hypoxia-driven intratumor heterogeneity and immune evasion
Terry, S., Engelsen, A. S. T., Buart, S., El‐Sayed, W., Venkatesh, G. H., & Chouaı̈b, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.004 · Cited by 102
Rizzo, A., & Ricci, A. D. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1972969 · Cited by 101
Federico, A. D., Rizzo, A., Carloni, R., Giglio, A. D., Bruno, R., Ricci, D., & Brandi, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2009455 · Cited by 102
Zhang, N., Yang, X., Piao, M., Xun, Z., Wang, Y., Ning, C., Zhang, L., Zhang, L., Wang, S., Wang, S., et al. (2024) · Biomarker Research · doi:10.1186/s40364-023-00535-z · Cited by 104
Self-citationKurebayashi, Y., Matsuda, K., Ueno, A., Tsujikawa, H., Yamazaki, K., Masugi, Y., Kwa, W. T., Effendi, K., Hasegawa, Y., Yagi, H., et al. (2021) · Hepatology · doi:10.1002/hep.32201 · Cited by 101
Kobayashi, Y., Lim, S., & Yamaguchi, H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.011 · Cited by 96
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 94
Cai, N., Cheng, K., Ma, Y., Liu, S., Tao, R., Li, Y., Li, D., Guo, B., Jia, W., Liang, H., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-331342 · Cited by 94
Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 95
Liao, H., Long, Y., Han, R., Wang, W., Xu, L., Liao, M., Zhang, Z., Wu, Z., Shang, X., Li, X., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.102 · Cited by 92
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
Ghasemi, A., Martínez-Usatorre, A., Li, L., Hicham, M., Guichard, A., Marcone, R., Fournier, N., Torchia, B., Bedoya, D. M., Davanture, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00668-y · Cited by 96
Metadata
- Authors
- Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., Villacorta-Martin, C., Singhi, A. D., Moghe, A., von Felden, J., Tal Grinspan, L., Wang, S., Kamphorst, A. O., Monga, S. P., Brown, B. D., Villanueva, A., Llovet, J. M., Merad, M., & Lujambio, A.
- Affiliations
- 1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
- Tisch Cancer Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- 2Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- University of Pittsburgh (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Lujambio, Amaia
- ORCID
- Ruiz de Galarreta, Marina
- Molina-Sánchez, Pedro
- Lindblad, Katherine E.
- Maier, Barbara
- Sia, Daniela
- Puigvehi, Marc
- Miguela, Verónica
- Casanova-Acebes, María
- Dhainaut, Maxime
- Singhi, Aatur D.
- Moghe, Akshata
- von Felden, Johann
- Wang, Shuang
- Kamphorst, Alice O.
- Monga, Satdarshan P.
- Brown, Brian D.
- Villanueva, Augusto
- Llovet, Josep M.
- Lujambio, Amaia
- Venue
- Cancer Discovery
- Published
- 2019-08-01
- Volume
- 9
- Issue
- 8
- Pages
- 1124-1141
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6677618
- OpenAlex
- W2952311394
- Cited by
- 912
- References
- 67
- Citations by year
- 2026: 114 · 2025: 121 · 2024: 158 · 2023: 169 · 2022: 156 · 2021: 116 · 2020: 67 · 2019: 11
- FWCI
- 36.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research FoundationDamon Runyon Cancer Research Foundation (Damon Runyon) (DR52-18)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R37CA230636, P30 CA196521)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- β-catenin signaling, hepatocellular carcinoma, immune evasion, anti-PD-1 resistance, PD-1 inhibitors, tumor surveillance, c-Myc, Trp53, dendritic cell recruitment, T cell function, RANTES, chemokines, genetically engineered mouse models, immunotherapy biomarkers
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Dendritic Cells, Disease Models, Animal, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Oncogenes, Biomarkers, Tumor, Signal Transduction, Gene Expression, Treatment Outcome, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Tumor Escape, Xenograft Model Antitumor Assays, Cell Line, Tumor, beta Catenin, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
